Search

Your search keyword '"de Vos F"' showing total 33 results
Start Over Author "de Vos F" Publication Type Electronic Resources
33 results on '"de Vos F"'

1. Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011–2020)

Author

Padilla, C. S., Ho, V. K.Y., Mooijenkind, T. W.A.N., Louwman, M. W.J., de Vos, F. Y.F.L., Bekkenk, M. W., Minnaard, W. A., Loef, C., van Zanten, S. E.M.Veldhuijzen, Padilla, C. S., Ho, V. K.Y., Mooijenkind, T. W.A.N., Louwman, M. W.J., de Vos, F. Y.F.L., Bekkenk, M. W., Minnaard, W. A., Loef, C., and van Zanten, S. E.M.Veldhuijzen

Abstract

Background: Although patients with melanoma of unknown primary (MUP) have a better prognosis than similar-staged melanoma patients with known primary, the occurrence of brain metastases (BM) entails a serious complication. This study provides an overview of the incidence, treatment patterns, and overall survival (OS) of adult patients with BM-MUP in the Netherlands. Methods: BM-MUP cases were retrieved from the Netherlands Cancer Registry. Patient, disease and treatment-related characteristics were summarised using descriptive statistics. Overall survival (OS) was calculated by the Kaplan–Meier method, and the impact of prognostic factors on OS was assessed using Cox proportional hazard regression analyses. Results: Among 1779 MUP patients, 450 were identified as BM-MUP (25.3%). Of these patients, 381 (84.7%) presented with BM along with other metastases, while 69 (15.3%) had BM only. BM-MUP patients were predominantly male (68.2%), and had a median age of 64 years at diagnosis (interquartile range 54–71 years). Over time, the proportion of BM along other metastatic sites increased, and the occurrence of BM decreased (p = 0.01). 1-Year OS improved for the total population, from 30.0% (95% confidence interval (CI): 19.8–40.9%) in 2011–2012 to 43.6% (95%CI: 34.5–52.3%) in 2019–2020, and median OS more than doubled from 4.2 months (95%CI: 3.3–6.2 months) to 9.8 months (95%CI: 7.0–13.2 months). Patient’s age, localisation of BM, presence of synchronous liver metastasis and treatment were identified as independent predictors of OS. Conclusion: Notwithstanding the progress made in OS for patients with BM-MUP in the past decade, their overall prognosis remains poor, and further efforts are needed to improve outcomes.

Published
2023

2. Medulloblastoma in adults:evaluation of the Dutch society for neuro-oncology treatment protocol

Author

Bleeker, L., Kouwenhoven, M. C.M., de Heer, I., Lissenberg-Witte, B. I., Gijsbers, A. H., Dubbink, H. J., Kros, J. M., Gijtenbeek, J. M.M., Kurt, E., van der Rijt, C. C.D., Swaak-Kragten, A. T., de Vos, F. Y., van der Weide, H. L., French, P. J., van den Bent, M. J., Wesseling, P., Bromberg, J. E.C., Bleeker, L., Kouwenhoven, M. C.M., de Heer, I., Lissenberg-Witte, B. I., Gijsbers, A. H., Dubbink, H. J., Kros, J. M., Gijtenbeek, J. M.M., Kurt, E., van der Rijt, C. C.D., Swaak-Kragten, A. T., de Vos, F. Y., van der Weide, H. L., French, P. J., van den Bent, M. J., Wesseling, P., and Bromberg, J. E.C.

Abstract

Purpose: Medulloblastoma is a rare tumor in adults. The objective of this nationwide, multicenter study was to evaluate the toxicity and efficacy of the Dutch treatment protocol for adult medulloblastoma patients. Methods: Adult medulloblastoma patients diagnosed between 2010 and 2018 were identified in the Dutch rare tumors registry or nationwide pathology database. Patients with intention to treat according to the national treatment protocol were included. Risk stratification was performed based on residual disease, histological subtype and extent of disease. All patients received postoperative radiotherapy [craniospinal axis 36 Gy/fossa posterior boost 19.8 Gy (14.4 Gy in case of metastases)]. High-risk patients received additional neoadjuvant (carboplatin-etoposide), concomitant (vincristine) and adjuvant chemotherapy (carboplatin-vincristine-cyclophosphamide) as far as feasible by toxicity. Methylation profiling, and additional next-generation sequencing in case of SHH-activated medulloblastomas, were performed. Results: Forty-seven medulloblastoma patients were identified, of whom 32 were treated according to the protocol. Clinical information and tumor material was available for 28 and 20 patients, respectively. The histological variants were mainly classic (43%) and desmoplastic medulloblastoma (36%). Sixteen patients (57%) were considered standard-risk and 60% were SHH-activated medulloblastomas. Considerable treatment reductions and delays in treatment occurred due to especially hematological and neurotoxicity. Only one high-risk patient could complete all chemotherapy courses. 5-years progression-free survival (PFS) and overall survival (OS) for standard-risk patients appeared worse than for high-risk patients (PFS 69% vs. 90%, OS 81% vs. 90% respectively), although this wasn’t statistically significant. Conclusion: Combined chemo-radiotherapy is a toxic regimen for adult medulloblastoma patients that may result in improved

Published
2023

4. Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol

Author

MS Medische Oncologie, Cancer, Bleeker, L, Kouwenhoven, M C M, de Heer, I, Lissenberg-Witte, B I, Gijsbers, A H, Dubbink, H J, Kros, J M, Gijtenbeek, J M M, Kurt, E, van der Rijt, C C D, Swaak-Kragten, A T, de Vos, F Y, van der Weide, H L, French, P J, van den Bent, M J, Wesseling, P, Bromberg, J E C, MS Medische Oncologie, Cancer, Bleeker, L, Kouwenhoven, M C M, de Heer, I, Lissenberg-Witte, B I, Gijsbers, A H, Dubbink, H J, Kros, J M, Gijtenbeek, J M M, Kurt, E, van der Rijt, C C D, Swaak-Kragten, A T, de Vos, F Y, van der Weide, H L, French, P J, van den Bent, M J, Wesseling, P, and Bromberg, J E C

Published
2023

5. Blended online learning for oncologists to improve skills in shared decision making about palliative chemotherapy: a pre-posttest evaluation

Author

MS Medische Oncologie, Cancer, Bos-van den Hoek, D W, van Laarhoven, H W M, Ali, R, Bakker, S D, Goosens, A, Hendriks, M P, Pepels, M J A E, Tange, D, de Vos, F Y F L, van de Wouw, A J, Smets, E M A, Henselmans, I, MS Medische Oncologie, Cancer, Bos-van den Hoek, D W, van Laarhoven, H W M, Ali, R, Bakker, S D, Goosens, A, Hendriks, M P, Pepels, M J A E, Tange, D, de Vos, F Y F L, van de Wouw, A J, Smets, E M A, and Henselmans, I

Published
2023

6. Prognostic factors among patients with brain metastases from cancer of unknown primary site

Author

Neurochirurgie, Cancer, MS Medische Oncologie, Simões Padilla, C, Ho, V K Y, van der Strate, I H, Leenders, W P J, de Vos, F Y F L, Veldhuijzen van Zanten, S E M, Loef, C, Neurochirurgie, Cancer, MS Medische Oncologie, Simões Padilla, C, Ho, V K Y, van der Strate, I H, Leenders, W P J, de Vos, F Y F L, Veldhuijzen van Zanten, S E M, and Loef, C

Published
2022

7. Prognostic factors among patients with brain metastases from cancer of unknown primary site

Author

Simões Padilla, C., Ho, V. K.Y., van der Strate, I. H., Leenders, W. P.J., de Vos, F. Y.F.L., Veldhuijzen van Zanten, S. E.M., Loef, C., Simões Padilla, C., Ho, V. K.Y., van der Strate, I. H., Leenders, W. P.J., de Vos, F. Y.F.L., Veldhuijzen van Zanten, S. E.M., and Loef, C.

Abstract

Purpose: Cancers of an unknown primary site (CUPs) have a dismal prognosis, and the situation is even worse for CUPs patients with brain metastases (BM-CUPs). This study aims to give better insight into the occurrence and survival of BM-CUPs patients. Methods: Cases were selected from the Netherlands Cancer Registry (1,430 BM-CUPs/17,140 CUPs). Baseline characteristics between CUPs patients with and without BM were tested using chi-square tests and Mann–Whitney U tests. Patients’ overall survival (OS) times were estimated by the Kaplan–Meier method and prognostic factors on OS was assessed using Cox proportional hazards regression analyses. Results: The proportion of BM-CUPs patients among CUPs increased from 8% in 2009–2010 to 10% in 2017–2018 (p < 0.001). Most patients presented with multiple brain lesions (53%). Survival of BM-CUPs improved over time: one-year OS increased from 10% for patients diagnosed in 2009–2010 to 17% (2017- 2018) (p < 0.01), and median survival times increased from 1.8 months to 2.2 months. Independent predictors of poor survival were multiple (HR 1.25; p < 0.01) or unknown (HR 1.48; p < 0.01) locations of BM, unknown/poorly/undifferentiated carcinoma histology (HR 1.53; p < 0.01), or clinical symptoms of BM (HR 1.74; p < 0.01), accompanying liver metastasis (HR 1.43; p < 0.01) and more than one metastatic site outside the brain compared to none (HR 1.52; p < 0.01). Conclusion: The incidence of patients with BM-CUPs is steadily increasing over time and overall prognosis remains dismal. Our results, however, show distinct patient subgroups that exhibit comparatively better outcomes, and more predictors may likely still be identified.

Published
2022

8. CONVENTIONAL MRI CRITERIA DIFFERENTIATE TRUE TUMOUR PROGRESSION FROM TREATMENT-INDUCED EFFECTS IN IRRADIATED WHO GRADE 3 AND 4 GLIOMAS

Author

Onderzoek NCH, MS Radiotherapie, Cancer, MS Medische Oncologie, Neurologen, Neurochirurgie, Brain, Divisie Beeld, MS Radiologie, Circulatory Health, Flies, C. M., van Leuken, K. H., Verhoeff, J. J. C., de Vos, F. Y. F., Seute, T., Robe, P. A., Hendrikse, J., Witkamp, T. D., Dankbaar, J. W., Snijders, T. J., Onderzoek NCH, MS Radiotherapie, Cancer, MS Medische Oncologie, Neurologen, Neurochirurgie, Brain, Divisie Beeld, MS Radiologie, Circulatory Health, Flies, C. M., van Leuken, K. H., Verhoeff, J. J. C., de Vos, F. Y. F., Seute, T., Robe, P. A., Hendrikse, J., Witkamp, T. D., Dankbaar, J. W., and Snijders, T. J.

Published
2021

9. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Author

Bent, M.J. (Martin) van den, Eoli, M. (Marica), Sepulveda, J.M. (Juan Manuel), Smits, M. (Marion), Walenkamp, A.M.E. (Annemiek M.), Frenel, J.-S. (Jean-Sebastian), Franceschi, C. (Claudio), Clement, P.M.J. (Paul), Chinot, O., De Vos, F. (Filip), Whenham, N. (Nicolas), Sanghera, P. (Paul), Weller, M. (Michael), Dubbink, H.J. (Erik Jan), French, P.J. (Pim), Looman, J. (Jim), Dey, J. (Jyotirmoy), Krause, S. (Scott), Ansell, P. (Pete), Nuyens, S. (Sarah), Spruyt, M. (Maarten), Brilhante, J. (Joana), Coens, C. (Corneel), Gorlia, T.S. (Thierry), Golfinopoulos, V. (Vassilis), Bent, M.J. (Martin) van den, Eoli, M. (Marica), Sepulveda, J.M. (Juan Manuel), Smits, M. (Marion), Walenkamp, A.M.E. (Annemiek M.), Frenel, J.-S. (Jean-Sebastian), Franceschi, C. (Claudio), Clement, P.M.J. (Paul), Chinot, O., De Vos, F. (Filip), Whenham, N. (Nicolas), Sanghera, P. (Paul), Weller, M. (Michael), Dubbink, H.J. (Erik Jan), French, P.J. (Pim), Looman, J. (Jim), Dey, J. (Jyotirmoy), Krause, S. (Scott), Ansell, P. (Pete), Nuyens, S. (Sarah), Spruyt, M. (Maarten), Brilhante, J. (Joana), Coens, C. (Corneel), Gorlia, T.S. (Thierry), and Golfinopoulos, V. (Vassilis)

Abstract

BACKGROUND: Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody-drug conjugate consisting of an antibody (ABT-806) directed against activated epidermal growth factor receptor (EGFR) and the toxin monomethylauristatin-F. We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma. METHODS: Eligible were patients with centrally confirmed EGFR amplified glioblastoma at first recurrence after chemo-irradiation with temozolomide. Patients were randomized to either Depatux-M 1.25 mg/kg every 2 weeks intravenously, or this treatment combined with temozolomide 150-200 mg/m2 day 1-5 every 4 weeks, or either lomustine or temozolomide. The primary endpoint of the study was overall survival. RESULTS: Two hundred sixty patients were randomized. In the primary efficacy analysis with 199 events (median follow-up 15.0 mo), the hazard ratio (HR) for the combination arm compared with the control arm was 0.71 (95% CI = 0.50, 1.02; P = 0.062). The efficacy of Depatux-M monotherapy was comparable to that of the control arm (HR = 1.04, 95% CI = 0.73, 1.48; P = 0.83). The most frequent toxicity in Depatux-M treated patients was a reversible corneal epitheliopathy, occurring as grades 3-4 adverse events in 25-30% of patients. In the long-term follow-up analysis with median follow-up of 28.7 months, the HR for the comparison of the combination arm versus the control arm was 0.66 (95% CI = 0.48, 0.93). CONCLUSION: This trial suggests a possible role for the use of Depatux-M in combination with temozolomide in EGFR amplified recurrent glioblastoma, especially in patients relapsing well after the end of first-line adjuvant temozolomide treatment. (NCT02343406).

Published
2020
Full Text
View/download PDF

10. Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool

Author

Priesterbach-Ackley, L. P., Boldt, H. B., Petersen, J. K., Bervoets, N., Scheie, D., Ulhøi, B. P., Gardberg, M., Brännström, T., Torp, S. H., Aronica, E., Küsters, B., den Dunnen, W. F.A., de Vos, F. Y.F.L., Wesseling, P., de Leng, W. W.J., Kristensen, B. W., Priesterbach-Ackley, L. P., Boldt, H. B., Petersen, J. K., Bervoets, N., Scheie, D., Ulhøi, B. P., Gardberg, M., Brännström, T., Torp, S. H., Aronica, E., Küsters, B., den Dunnen, W. F.A., de Vos, F. Y.F.L., Wesseling, P., de Leng, W. W.J., and Kristensen, B. W.

Abstract

Aims: Methylation profiling (MP) is increasingly incorporated in the diagnostic process of central nervous system (CNS) tumours at our centres in The Netherlands and Scandinavia. We aimed to identify the benefits and challenges of MP as a support tool for CNS tumour diagnostics. Methods: About 502 CNS tumour samples were analysed using (850 k) MP. Profiles were matched with the DKFZ/Heidelberg CNS Tumour Classifier. For each case, the final pathological diagnosis was compared to the diagnosis before MP. Results: In 54.4% (273/502) of all analysed cases, the suggested methylation class (calibrated score ≥0.9) corresponded with the initial pathological diagnosis. The diagnosis of 24.5% of these cases (67/273) was more refined after incorporation of the MP result. In 9.8% of cases (49/502), the MP result led to a new diagnosis, resulting in an altered WHO grade in 71.4% of these cases (35/49). In 1% of cases (5/502), the suggested class based on MP was initially disregarded/interpreted as misleading, but in retrospect, the MP result predicted the right diagnosis for three of these cases. In six cases, the suggested class was interpreted as ‘discrepant but noncontributory’. The remaining 33.7% of cases (169/502) had a calibrated score <0.9, including 7.8% (39/502) for which no class indication was given at all (calibrated score <0.3). Conclusions: MP is a powerful tool to confirm and fine-tune the pathological diagnosis of CNS tumours, and to avoid misdiagnoses. However, it is crucial to interpret the results in the context of clinical, radiological, histopathological and other molecular information.

Published
2020

11. Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool

Author

Priesterbach-Ackley, L. P., Boldt, H. B., Petersen, J. K., Bervoets, N., Scheie, D., Ulhøi, B. P., Gardberg, M., Brännström, T., Torp, S. H., Aronica, E., Küsters, B., den Dunnen, W. F.A., de Vos, F. Y.F.L., Wesseling, P., de Leng, W. W.J., Kristensen, B. W., Priesterbach-Ackley, L. P., Boldt, H. B., Petersen, J. K., Bervoets, N., Scheie, D., Ulhøi, B. P., Gardberg, M., Brännström, T., Torp, S. H., Aronica, E., Küsters, B., den Dunnen, W. F.A., de Vos, F. Y.F.L., Wesseling, P., de Leng, W. W.J., and Kristensen, B. W.

Abstract

Aims: Methylation profiling (MP) is increasingly incorporated in the diagnostic process of central nervous system (CNS) tumours at our centres in The Netherlands and Scandinavia. We aimed to identify the benefits and challenges of MP as a support tool for CNS tumour diagnostics. Methods: About 502 CNS tumour samples were analysed using (850 k) MP. Profiles were matched with the DKFZ/Heidelberg CNS Tumour Classifier. For each case, the final pathological diagnosis was compared to the diagnosis before MP. Results: In 54.4% (273/502) of all analysed cases, the suggested methylation class (calibrated score ≥0.9) corresponded with the initial pathological diagnosis. The diagnosis of 24.5% of these cases (67/273) was more refined after incorporation of the MP result. In 9.8% of cases (49/502), the MP result led to a new diagnosis, resulting in an altered WHO grade in 71.4% of these cases (35/49). In 1% of cases (5/502), the suggested class based on MP was initially disregarded/interpreted as misleading, but in retrospect, the MP result predicted the right diagnosis for three of these cases. In six cases, the suggested class was interpreted as ‘discrepant but noncontributory’. The remaining 33.7% of cases (169/502) had a calibrated score <0.9, including 7.8% (39/502) for which no class indication was given at all (calibrated score <0.3). Conclusions: MP is a powerful tool to confirm and fine-tune the pathological diagnosis of CNS tumours, and to avoid misdiagnoses. However, it is crucial to interpret the results in the context of clinical, radiological, histopathological and other molecular information.

Published
2020

12. Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool

Author

Pathologie Opleiding, PMC Medisch specialisten, MS Medische Oncologie, Cancer, Pathologie Pathologen staf, Priesterbach-Ackley, L P, Boldt, H B, Petersen, J K, Bervoets, N, Scheie, D, Ulhøi, B P, Gardberg, M, Brännström, T, Torp, S H, Aronica, E, Küsters, B, den Dunnen, W F A, de Vos, F Y F L, Wesseling, P, de Leng, W W J, Kristensen, B W, Pathologie Opleiding, PMC Medisch specialisten, MS Medische Oncologie, Cancer, Pathologie Pathologen staf, Priesterbach-Ackley, L P, Boldt, H B, Petersen, J K, Bervoets, N, Scheie, D, Ulhøi, B P, Gardberg, M, Brännström, T, Torp, S H, Aronica, E, Küsters, B, den Dunnen, W F A, de Vos, F Y F L, Wesseling, P, de Leng, W W J, and Kristensen, B W

Published
2020

14. Single-subject classification of presymptomatic frontotemporal dementia mutation carriers using multimodal MRI

Author

Feis, R.A. (Rogier A.), Bouts, M.J.R.J. (Mark J.R.J.), Panman, J.L. (Jessica), Jiskoot, L.C. (Lize), Dopper, E.G.P. (Elise), Schouten, T.M. (Tijn M.), de Vos, F. (Frank), van der Grond, J. (Jeroen), Swieten, J.C. (John) van, Rombouts, S.A.R.B. (Serge), Feis, R.A. (Rogier A.), Bouts, M.J.R.J. (Mark J.R.J.), Panman, J.L. (Jessica), Jiskoot, L.C. (Lize), Dopper, E.G.P. (Elise), Schouten, T.M. (Tijn M.), de Vos, F. (Frank), van der Grond, J. (Jeroen), Swieten, J.C. (John) van, and Rombouts, S.A.R.B. (Serge)

Abstract

Background: Classification models based on magnetic resonance imaging (MRI) may aid early diagnosis of frontotemporal dementia (FTD) but have only been applied in established FTD cases. Detection of FTD patients in earlier disease stages, such as presymptomatic mutation carriers, may further advance early diagnosis and treatment. In this study, we aim to distinguish presymptomatic FTD mutation carriers from controls on an individual level using multimodal MRI-based classification. Methods: Anatomical MRI, diffusion tensor imaging (DTI) and resting-state functional MRI data were collected in 55 presymptomatic FTD mutation carriers (8 microtubule-associated protein Tau, 35 progranulin, and 12 chromosome 9 open reading frame 72) and 48 familial controls. We calculated grey and white matter density features from anatomical MRI scans, diffusivity features from DTI, and functional connectivity features from resting-state functional MRI. These features were applied in a recently introduced multimodal behavioural variant FTD (bvFTD) classification model, and were subsequently used to train and test unimodal and multimodal carrier-control models. Classification performance was quantified using area under the receiver operator characteristic curves (AUC). Results: The bvFTD model was not able to separate presymptomatic carriers from controls beyond chance level (AUC = 0.570, p = 0.11). In contrast, one unimodal and several multimodal carrier-control models performed significantly better than chance level. The unimodal model included the radial diffusivity feature and had an AUC of 0.646 (p = 0.021). The best multimodal model combined radial diffusivity and white matter density features (AUC = 0.680, p = 0.005). Conclusions: FTD mutation carriers can be separated from controls with a modest AUC even before symptom-onset, using a newly created carrier-control classification model, while this was not possible using a recent bvFTD classification model. A multimodal MRI-based clas

Published
2018
Full Text
View/download PDF

17. A randomized controlled trial of a skills training for oncologists and a communication aid for patients to stimulate shared decision making about palliative systemic treatment (CHOICE): study protocol

Author

MS Medische Oncologie, Cancer, Henselmans, I, Smets, Ellen M A, de Haes, J.C.J.M., Dijkgraaf, Marcel G. W., de Vos, F Y, van Laarhoven, Hanneke W M, MS Medische Oncologie, Cancer, Henselmans, I, Smets, Ellen M A, de Haes, J.C.J.M., Dijkgraaf, Marcel G. W., de Vos, F Y, and van Laarhoven, Hanneke W M

Published
2018

19. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma : Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study

Author

van der Hiel, Bernies, Haanen, John B A G, Stokkel, Marcel P M, Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H, van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J M, van Tinteren, H., Wessels, Lodewyk F A, Lolkema, Martijn P J K, Hoekstra, Otto S, Hospers, Geke A P, Brouwers, Adrienne H, Koornstra, R.H.T., Arens, A. I. J., de Vos, F. Y.F.L., Hobbelink, M. G.G., Kapiteijn, H. W., de Geus-Oei, L. F., Kruit, W. H.J., Verzijlbergen, F.J., Aarts, M. J.B., Mottaghy, F. M., de Groot, J. W.B., Knollema, S., Piersma, D., Agool, A., Vreugdenhil, Art, Liem, I H, van den Berkmortel, Franchette W P J, Schreurs, M.W., REPOSIT study group, van der Hiel, Bernies, Haanen, John B A G, Stokkel, Marcel P M, Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H, van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J M, van Tinteren, H., Wessels, Lodewyk F A, Lolkema, Martijn P J K, Hoekstra, Otto S, Hospers, Geke A P, Brouwers, Adrienne H, Koornstra, R.H.T., Arens, A. I. J., de Vos, F. Y.F.L., Hobbelink, M. G.G., Kapiteijn, H. W., de Geus-Oei, L. F., Kruit, W. H.J., Verzijlbergen, F.J., Aarts, M. J.B., Mottaghy, F. M., de Groot, J. W.B., Knollema, S., Piersma, D., Agool, A., Vreugdenhil, Art, Liem, I H, van den Berkmortel, Franchette W P J, Schreurs, M.W., and REPOSIT study group

Published
2017

20. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma : Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study

Author

van der Hiel, Bernies, Haanen, John B A G, Stokkel, Marcel P M, Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H, van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J M, van Tinteren, H., Wessels, Lodewyk F A, Lolkema, Martijn P J K, Hoekstra, Otto S, Hospers, Geke A P, Brouwers, Adrienne H, Koornstra, R.H.T., Arens, A. I. J., de Vos, F. Y.F.L., Hobbelink, M. G.G., Kapiteijn, H. W., de Geus-Oei, L. F., Kruit, W. H.J., Verzijlbergen, F.J., Aarts, M. J.B., Mottaghy, F. M., de Groot, J. W.B., Knollema, S., Piersma, D., Agool, A., Vreugdenhil, Art, Liem, I H, van den Berkmortel, Franchette W P J, Schreurs, M.W., REPOSIT study group, van der Hiel, Bernies, Haanen, John B A G, Stokkel, Marcel P M, Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H, van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J M, van Tinteren, H., Wessels, Lodewyk F A, Lolkema, Martijn P J K, Hoekstra, Otto S, Hospers, Geke A P, Brouwers, Adrienne H, Koornstra, R.H.T., Arens, A. I. J., de Vos, F. Y.F.L., Hobbelink, M. G.G., Kapiteijn, H. W., de Geus-Oei, L. F., Kruit, W. H.J., Verzijlbergen, F.J., Aarts, M. J.B., Mottaghy, F. M., de Groot, J. W.B., Knollema, S., Piersma, D., Agool, A., Vreugdenhil, Art, Liem, I H, van den Berkmortel, Franchette W P J, Schreurs, M.W., and REPOSIT study group

Published
2017

21. Interlaboratory variability of Ki67 staining in breast cancer

Author

Focke, Cornelia M., Bürger, Horst, van Diest, Paul J., Finsterbusch, Kai, Gläser, Doreen, Korsching, Eberhard, Decker, Thomas, Anders, M., Bollmann, R., Eiting, Fr, Friedrich, K., Habeck, J. O., Haroske, G., Hinrichs, B., Behrens, A., Krause, Lars Udo, Braun-Lang, U., Lorenzen, J., Minew, N., Mlynek-Kersjes, M., Nenning, H., Packeisen, J., Poche-de Vos, F., Reyher-Klein, S., Rothacker, D., Schultz, M., Sturm, U., Tawfik, M., Berghäuser, K. H., Böcker, W, Cserni, G., Habedank, S., Lax, S., Moinfar, F., Regitnig, P., Reiner-Concin, A., Rüschoff, J., Varga, Z., Woziwodski, J., German Breast Screening Pathology Initiative, Focke, Cornelia M., Bürger, Horst, van Diest, Paul J., Finsterbusch, Kai, Gläser, Doreen, Korsching, Eberhard, Decker, Thomas, Anders, M., Bollmann, R., Eiting, Fr, Friedrich, K., Habeck, J. O., Haroske, G., Hinrichs, B., Behrens, A., Krause, Lars Udo, Braun-Lang, U., Lorenzen, J., Minew, N., Mlynek-Kersjes, M., Nenning, H., Packeisen, J., Poche-de Vos, F., Reyher-Klein, S., Rothacker, D., Schultz, M., Sturm, U., Tawfik, M., Berghäuser, K. H., Böcker, W, Cserni, G., Habedank, S., Lax, S., Moinfar, F., Regitnig, P., Reiner-Concin, A., Rüschoff, J., Varga, Z., Woziwodski, J., and German Breast Screening Pathology Initiative

Published
2017

23. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma : Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study

Author

van der Hiel, Bernies, Haanen, John B A G, Stokkel, Marcel P M, Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H, van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J M, van Tinteren, H., Wessels, Lodewyk F A, Lolkema, Martijn P J K, Hoekstra, Otto S, Hospers, Geke A P, Brouwers, Adrienne H, Koornstra, R.H.T., Arens, A. I. J., de Vos, F. Y.F.L., Hobbelink, M. G.G., Kapiteijn, H. W., de Geus-Oei, L. F., Kruit, W. H.J., Verzijlbergen, F.J., Aarts, M. J.B., Mottaghy, F. M., de Groot, J. W.B., Knollema, S., Piersma, D., Agool, A., Vreugdenhil, Art, Liem, I H, van den Berkmortel, Franchette W P J, Schreurs, M.W., REPOSIT study group, van der Hiel, Bernies, Haanen, John B A G, Stokkel, Marcel P M, Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H, van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J M, van Tinteren, H., Wessels, Lodewyk F A, Lolkema, Martijn P J K, Hoekstra, Otto S, Hospers, Geke A P, Brouwers, Adrienne H, Koornstra, R.H.T., Arens, A. I. J., de Vos, F. Y.F.L., Hobbelink, M. G.G., Kapiteijn, H. W., de Geus-Oei, L. F., Kruit, W. H.J., Verzijlbergen, F.J., Aarts, M. J.B., Mottaghy, F. M., de Groot, J. W.B., Knollema, S., Piersma, D., Agool, A., Vreugdenhil, Art, Liem, I H, van den Berkmortel, Franchette W P J, Schreurs, M.W., and REPOSIT study group

Published
2017

24. Interlaboratory variability of Ki67 staining in breast cancer

Author

Focke, Cornelia M., Bürger, Horst, van Diest, Paul J., Finsterbusch, Kai, Gläser, Doreen, Korsching, Eberhard, Decker, Thomas, Anders, M., Bollmann, R., Eiting, Fr, Friedrich, K., Habeck, J. O., Haroske, G., Hinrichs, B., Behrens, A., Krause, Lars Udo, Braun-Lang, U., Lorenzen, J., Minew, N., Mlynek-Kersjes, M., Nenning, H., Packeisen, J., Poche-de Vos, F., Reyher-Klein, S., Rothacker, D., Schultz, M., Sturm, U., Tawfik, M., Berghäuser, K. H., Böcker, W, Cserni, G., Habedank, S., Lax, S., Moinfar, F., Regitnig, P., Reiner-Concin, A., Rüschoff, J., Varga, Z., Woziwodski, J., German Breast Screening Pathology Initiative, Focke, Cornelia M., Bürger, Horst, van Diest, Paul J., Finsterbusch, Kai, Gläser, Doreen, Korsching, Eberhard, Decker, Thomas, Anders, M., Bollmann, R., Eiting, Fr, Friedrich, K., Habeck, J. O., Haroske, G., Hinrichs, B., Behrens, A., Krause, Lars Udo, Braun-Lang, U., Lorenzen, J., Minew, N., Mlynek-Kersjes, M., Nenning, H., Packeisen, J., Poche-de Vos, F., Reyher-Klein, S., Rothacker, D., Schultz, M., Sturm, U., Tawfik, M., Berghäuser, K. H., Böcker, W, Cserni, G., Habedank, S., Lax, S., Moinfar, F., Regitnig, P., Reiner-Concin, A., Rüschoff, J., Varga, Z., Woziwodski, J., and German Breast Screening Pathology Initiative

Published
2017

25. Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide

Author

Verpleegafdeling Hematologie, UMC Utrecht, ZL Neuro-Oncologie Medisch, Brain, MS Interne Geneeskunde, Pathologie Groep Brosens, Pathologie Pathologen staf, Cancer, van Der Vlist, A., Snijders, T. J., Stades, A. M.E., Spliet, W. G.M., De Vos, F. Y.F.L., Verpleegafdeling Hematologie, UMC Utrecht, ZL Neuro-Oncologie Medisch, Brain, MS Interne Geneeskunde, Pathologie Groep Brosens, Pathologie Pathologen staf, Cancer, van Der Vlist, A., Snijders, T. J., Stades, A. M.E., Spliet, W. G.M., and De Vos, F. Y.F.L.

Published
2017

26. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study

Author

MS Medische Oncologie, Cancer, UMC Utrecht, Arts-assistenten Nucleaire Geneesk., van der Hiel, Bernies, Haanen, John B A G, Stokkel, Marcel P M, Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H, van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J M, van Tinteren, H., Wessels, Lodewyk F A, Lolkema, Martijn P J K, Hoekstra, Otto S, Hospers, Geke A P, Brouwers, Adrienne H, Koornstra, R.H.T., Arens, A. I. J., de Vos, F. Y.F.L., Hobbelink, M. G.G., Kapiteijn, H. W., de Geus-Oei, L. F., Kruit, W. H.J., Verzijlbergen, F.J., Aarts, M. J.B., Mottaghy, F. M., de Groot, J. W.B., Knollema, S., Piersma, D., Agool, A., Vreugdenhil, Art, Liem, I H, van den Berkmortel, Franchette W P J, Schreurs, M.W., REPOSIT study group, MS Medische Oncologie, Cancer, UMC Utrecht, Arts-assistenten Nucleaire Geneesk., van der Hiel, Bernies, Haanen, John B A G, Stokkel, Marcel P M, Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H, van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J M, van Tinteren, H., Wessels, Lodewyk F A, Lolkema, Martijn P J K, Hoekstra, Otto S, Hospers, Geke A P, Brouwers, Adrienne H, Koornstra, R.H.T., Arens, A. I. J., de Vos, F. Y.F.L., Hobbelink, M. G.G., Kapiteijn, H. W., de Geus-Oei, L. F., Kruit, W. H.J., Verzijlbergen, F.J., Aarts, M. J.B., Mottaghy, F. M., de Groot, J. W.B., Knollema, S., Piersma, D., Agool, A., Vreugdenhil, Art, Liem, I H, van den Berkmortel, Franchette W P J, Schreurs, M.W., and REPOSIT study group

Published
2017

27. Interlaboratory variability of Ki67 staining in breast cancer

Author

Pathologie mortuarium en obductie, UMC Utrecht, Pathologie, Cancer, Focke, Cornelia M., Bürger, Horst, van Diest, Paul J., Finsterbusch, Kai, Gläser, Doreen, Korsching, Eberhard, Decker, Thomas, Anders, M., Bollmann, R., Eiting, Fr, Friedrich, K., Habeck, J. O., Haroske, G., Hinrichs, B., Behrens, A., Krause, Lars Udo, Braun-Lang, U., Lorenzen, J., Minew, N., Mlynek-Kersjes, M., Nenning, H., Packeisen, J., Poche-de Vos, F., Reyher-Klein, S., Rothacker, D., Schultz, M., Sturm, U., Tawfik, M., Berghäuser, K. H., Böcker, W, Cserni, G., Habedank, S., Lax, S., Moinfar, F., Regitnig, P., Reiner-Concin, A., Rüschoff, J., Varga, Z., Woziwodski, J., German Breast Screening Pathology Initiative, Pathologie mortuarium en obductie, UMC Utrecht, Pathologie, Cancer, Focke, Cornelia M., Bürger, Horst, van Diest, Paul J., Finsterbusch, Kai, Gläser, Doreen, Korsching, Eberhard, Decker, Thomas, Anders, M., Bollmann, R., Eiting, Fr, Friedrich, K., Habeck, J. O., Haroske, G., Hinrichs, B., Behrens, A., Krause, Lars Udo, Braun-Lang, U., Lorenzen, J., Minew, N., Mlynek-Kersjes, M., Nenning, H., Packeisen, J., Poche-de Vos, F., Reyher-Klein, S., Rothacker, D., Schultz, M., Sturm, U., Tawfik, M., Berghäuser, K. H., Böcker, W, Cserni, G., Habedank, S., Lax, S., Moinfar, F., Regitnig, P., Reiner-Concin, A., Rüschoff, J., Varga, Z., Woziwodski, J., and German Breast Screening Pathology Initiative

Published
2017

28. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

Author

Milojkovic Kerklaan, B., Slater, S, Flynn, M, Greystoke, A, Witteveen, P O, Megui-Roelvink, M, de Vos, F, Dean, E, Reyderman, L, Ottesen, L, Ranson, M, Lolkema, M P J, Plummer, R, Kristeleit, R, Evans, T R J, Schellens, J H M, Milojkovic Kerklaan, B., Slater, S, Flynn, M, Greystoke, A, Witteveen, P O, Megui-Roelvink, M, de Vos, F, Dean, E, Reyderman, L, Ottesen, L, Ranson, M, Lolkema, M P J, Plummer, R, Kristeleit, R, Evans, T R J, and Schellens, J H M

Published
2016

29. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

Author

Milojkovic Kerklaan, B., Slater, S., Flynn, M., Greystoke, A., Witteveen, P. O., Megui-Roelvink, M., de Vos, F., Dean, E., Reyderman, L., Ottesen, L., Ranson, M., Lolkema, M. P J, Plummer, R., Kristeleit, R., Evans, T. R J, Schellens, J. H M, Milojkovic Kerklaan, B., Slater, S., Flynn, M., Greystoke, A., Witteveen, P. O., Megui-Roelvink, M., de Vos, F., Dean, E., Reyderman, L., Ottesen, L., Ranson, M., Lolkema, M. P J, Plummer, R., Kristeleit, R., Evans, T. R J, and Schellens, J. H M

Published
2016

30. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

Author

Beije, N., Kraan, J., Taal, W., Van Der Holt, B., Oosterkamp, H. M., Walenkamp, A. M., Beerepoot, L., Hanse, M., Van Linde, M. E., Otten, A., Vernhout, R. M., De Vos, F. Y F, Gratama, J. W., Sleijfer, S., Van Den Bent, M. J., Beije, N., Kraan, J., Taal, W., Van Der Holt, B., Oosterkamp, H. M., Walenkamp, A. M., Beerepoot, L., Hanse, M., Van Linde, M. E., Otten, A., Vernhout, R. M., De Vos, F. Y F, Gratama, J. W., Sleijfer, S., and Van Den Bent, M. J.

Published
2015

31. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

Author

Beije, N., Kraan, J., Taal, W., Van Der Holt, B., Oosterkamp, H. M., Walenkamp, A. M., Beerepoot, L., Hanse, M., Van Linde, M. E., Otten, A., Vernhout, R. M., De Vos, F. Y F, Gratama, J. W., Sleijfer, S., Van Den Bent, M. J., Beije, N., Kraan, J., Taal, W., Van Der Holt, B., Oosterkamp, H. M., Walenkamp, A. M., Beerepoot, L., Hanse, M., Van Linde, M. E., Otten, A., Vernhout, R. M., De Vos, F. Y F, Gratama, J. W., Sleijfer, S., and Van Den Bent, M. J.

Published
2015

32. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

Author

Beije, N., Kraan, J., Taal, W., Van Der Holt, B., Oosterkamp, H. M., Walenkamp, A. M., Beerepoot, L., Hanse, M., Van Linde, M. E., Otten, A., Vernhout, R. M., De Vos, F. Y F, Gratama, J. W., Sleijfer, S., Van Den Bent, M. J., Beije, N., Kraan, J., Taal, W., Van Der Holt, B., Oosterkamp, H. M., Walenkamp, A. M., Beerepoot, L., Hanse, M., Van Linde, M. E., Otten, A., Vernhout, R. M., De Vos, F. Y F, Gratama, J. W., Sleijfer, S., and Van Den Bent, M. J.

Published
2015

33. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

Author

Unit Opleiding Aios, MS Medische Oncologie, Cancer, Beije, N., Kraan, J., Taal, W., Van Der Holt, B., Oosterkamp, H. M., Walenkamp, A. M., Beerepoot, L., Hanse, M., Van Linde, M. E., Otten, A., Vernhout, R. M., De Vos, F. Y F, Gratama, J. W., Sleijfer, S., Van Den Bent, M. J., Unit Opleiding Aios, MS Medische Oncologie, Cancer, Beije, N., Kraan, J., Taal, W., Van Der Holt, B., Oosterkamp, H. M., Walenkamp, A. M., Beerepoot, L., Hanse, M., Van Linde, M. E., Otten, A., Vernhout, R. M., De Vos, F. Y F, Gratama, J. W., Sleijfer, S., and Van Den Bent, M. J.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results